Open AccessA case report of prucalopride treatment in pediatric gastroparesis: a novel therapy
Author(s) -
Diana Paola Escobar-Serna,
Fernando Javier Peralta-Palmezano,
Juan Javier Peralta-Palmezano
Publication year - 2022
Publication title -
archivos argentinos de pediatría
Language(s) - English
Resource type - Journals
eISSN - 1668-3501
pISSN - 0325-0075
DOI - 10.5546/aap.2022.eng.e98
Subject(s) - medicine , gastroparesis , gastric emptying , gastroenterology , metoclopramide , domperidone , scintigraphy , anesthesia , vomiting , stomach , dopamine
Prucalopride has been used in adults with gastroparesis, accelerating gastric emptying. There are no studies with this drug in gastroparetic children. An 8-year-old boy is presented who consulted for a month of postprandial symptoms, with a diagnosis of gastroparesis by gastric emptying scintigraphy. He did not improve with metoclopramide, domperidone, erythromycin, and esomeprazole. He received prucalopride for two periods (for 178 and 376 days) at doses: 0.03 - 0.04 mg/ kg/day, presenting improvement in the follow-up with the cardinal gastroparesis symptom index and gastric emptying scintigraphy. Due to the good response, prucalopride may be a therapeutic option in pediatric gastroparesis.